The authors make no claims of the accuracy of the information contained
herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this document shall be liable for any special,
consequential, or exemplary damages resulting in whole or part from any
user's use of or reliance upon this material. PLEASE
READ THE DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Standard Dilutions [Amount of drug]
[Infusion volume] [Infusion rate]
Treat Vtach / V fib: 50 to 100mg (1 to 1.5 mg/kg) IV bolus (25 to 50
Decrease by 50% in elderly /CHF /Hepatic disease. Repeat bolus q3 to
5min until arrhythmia subsides or side effects (convulsions
Do not exceed 3 mg/ kg bolus in a 1 hour period.
IV infusion: 1 to 4 mg/ min.
Calculation of drip rate:
1 gram/250 ml (ml/hr) = mg/min x 15. Decrease rate by 50% after 24
DOSAGE AND ADMINISTRATION
------------------Adults: Single Direct Intravenous Injection (bolus): ONLY THE
5 mL, 50 MG or 100 MG DOSAGE SIZES should be used for direct
intravenous injection. The usual dose is 50 to 100 mg of lidocaine
hydrochloride (0.70 to 1.4 mg/kg; 0.32 to 0.63 mg/lb) administered
intravenously under ECG monitoring. This dose may be administered at
the rate of approximately 25 to 50 mg/min (0.35 to 0.70 mg/kg/min; 0.16
to 0.32 mg/lb/min). Sufficient time should be allowed to enable a slow
circulation to carry the drug to the site of action. If the initial
injection of 50 to 100 mg does not produce a desired response, a second
dose may be injected after five minutes. NO MORE THAN 200 TO 300 MG OF
LIDOCAINE HYDROCHLORIDE SHOULD BE ADMINISTERED DURING A ONE HOUR
Continuous Intravenous Infusion: Following bolus
administration, intravenous infusions of lidocaine hydrochloride may be
initiated at the rate of 1 to 4 mg/min of lidocaine hydrochloride
(0.014 to 0.057 mg/kg/min; 0.006 to 0.026 mg/lb/min). The rate of
intravenous infusions should be reassessed as soon as the patient’s
basic cardiac rhythm appears to be stable or at the earliest signs of
toxicity. It should rarely be necessary to continue intravenous
infusions of lidocaine for prolonged periods.
Solutions for intravenous infusion may be prepared by the addition of
one gram (or two grams) of lidocaine hydrochloride to one liter of 5%
dextrose in water using aseptic technique. Approximately a 0.1% (or
0.2%) solution will result from this procedure; that is, each
milliliter will contain approximately 1 mg (or 2 mg) of lidocaine
hydrochloride. In those cases in which fluid restriction is medically
appropriate, a more concentrated solution may be prepared.
Lidocaine Hydrochloride Injection, USP has been found to be chemically
stable for 24 hours after dilution in 5% dextrose in water. However, as
with all intravenous admixtures, dilution of the solution should be
made just prior to its administration.
When administering lidocaine hydrochloride (or any potent medication)
by continuous intravenous infusion, it is advisable to use a precision
volume control I.V. set.
-------------Pediatric: Controlled clinical studies in
the pediatric population to establish dosing schedules have not been
conducted. The American Heart Association’s Standards and Guidelines
recommends a bolus dose of 1 mg/kg, and an infusion rate of between
20-50 µg/kg/min for prolonged therapy. When drug clearance is reduced,
as in patients with shock, congestive heart failure or cardiac arrest,
the infusion rate should not exceed 20 µg/kg/min.
NOTE: Regarding Prolonged Infusions: There are data
that indicate the half-life may be 3 hours or longer following
infusions of greater than 24 hours in duration. Do not use if solution
is discolored or cloudy.
Parenteral drug products should be inspected visually for particulate
matter and discoloration prior to administration whenever solution and
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.